Mazdutide

Mazdutide is a dual GLP-1 and glucagon receptor agonist currently in clinical trials for obesity, where it is used to drive weight loss and appetite suppression. Users typically administer the peptide via subcutaneous injection at a modal dose of 1 mg, though reported usage spans a wide range from 100 µg to 12 mg without a standardized cycling protocol. While the substance is a focus of ongoing research, the primary tradeoff for the reader is that the off-label evidence base remains significantly thinner than current discourse suggests, and there is no insurance pathway for access outside of its clinical obesity indication.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.62.82.73.13.12.0

Research Evidence

Evidence shape

Mazdutide carries moderate clinical evidence, supported by 14 published human studies primarily focused on obesity and weight management. While the research pipeline is extensive with 34 registered trials, the breadth of data remains thin; only one trial has posted results, and the vast majority of the 23 mapped indications rely on single-trial, exploratory data. Despite the presence of Phase 3-grade research, the current evidence base is heavily skewed toward early-stage investigation, leaving most clinical applications without the validation of completed, large-scale, blinded trials.

Depthhow much
37 registered trials
18 completed · 1 with posted results · 19 recruiting / active · combined n=179
Breadthhow many areas
25 indications mapped
1 with results · 23 thin / exploratory · 1 animal-only · 18 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
1 blinded with results · 2 distinct sponsors · AE table from NCT06124807 · 10 linked publications on registered trials
Breadth and depth52 rows captured
Human
direct clinical signal
51
Animal
translational support
1
In vitro
mechanistic support
0
HighMediumLow

Anecdotal efficacy

Mazdutide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Peptx
--
100 mg
$90.00
$0.9/mg
2
Mrbeetoe
--
50 mg
$105.00
$2.1/mg
3
Bulk Peptide Supply
unknown
100 mg×10
$300.00
$3/mg
4
Prism Aminos
US
10 mg
$35.50
$3.55/mg
5
Badgercompounds
US
10 mg
$49.99
$5/mg
6
PeptidesSource
USA
10 mg
$60.00
$6/mg

price offers can be sorted by column

1-6 of 41

Mazdutide dosing & protocol

How Mazdutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 31
Typical dose
4 mg2 mg – 9 mg
typical
0
5 mg
10 mg
15 mg
distribution of 20 reported doses · darker = more
Frequency
weekly
Route
subQ

Mazdutide was administered subcutaneously at a typical dose of 4 mg once weekly in research trials, with individual studies using amounts between 2 mg and 9 mg per week.

31 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
5 mg
10 mg
15 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 21
Typical dose
1 mg100 µg – 12 mg
typical
0
5 mg
10 mg
15 mg
distribution of 25 reported doses · darker = more
Frequency
unspecified
Route
subQ

Community users typically dose Mazdutide at about 1 mg, with reported amounts spanning 0.6 mg up to 9 mg per week; weekly injections are the most frequently mentioned schedule, while a few users give a single dose without specifying frequency. No cycling patterns were reported.

21 sources

Related peptides

SemaglutideTirzepatideRetatrutideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensine